Cystadenocarcinoma — Trials

Cystadenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

37 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 5
Recruiting: 0
Ph III recruiting: 0
Growth YoY: —
Industry share: 0%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (6)

clinicaltrialsPublishedShowing 1–5 of 5 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02101775	Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	active not recruiting	Phase 2	124	National Cancer Institute (NCI)NIH	3	Sep 10, 2026	clinicaltrials
NCT01081262	Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer	active not recruiting	Phase 3	50	National Cancer Institute (NCI)NIH